[Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System].
Isandra Oliveira MeirellesDulce Helena Nunes CoutoRodrigo Saar da CostaPublished in: Cadernos de saude publica (2019)
Renal cancer is the 13th most frequent neoplasm in the world. From 2010 to 2014, renal cancer accounted for 1.43% of cancer deaths in Brazil. The treatment of choice for metastatic renal cancer is tyrosine kinase inhibitors (TKI) sunitinib and pazopanib. This article assesses cost-effectiveness between pazopanib and sunitinib in the treatment of metastatic renal cancer. A cost-effectiveness study was performed from the perspective of a federal hospital under the Brazilian Unified National Health System (SUS). TKI effectiveness and safety outcomes were applied to the decision tree model. Clinical data were extracted from patient charts, and direct costs were consulted from official Ministry of Health sources. The cost of 10 months of treatment, including the costs of the TKI, procedures and management of adverse events, was BRL 98,677.19 for pazopanib and BRL 155,227.11 for sunitinib. The drugs displayed statistically equivalent effectiveness and statistically different safety outcomes, with pazopanib displaying better results. In this setting, pazopanib is the dominant technology when the treatment costs are analyzed together with the costs of managing adverse events.
Keyphrases
- papillary thyroid
- metastatic renal cell carcinoma
- squamous cell carcinoma
- small cell lung cancer
- healthcare
- lymph node metastasis
- public health
- systematic review
- emergency department
- renal cell carcinoma
- childhood cancer
- machine learning
- adipose tissue
- social media
- type diabetes
- combination therapy
- quality improvement
- climate change
- skeletal muscle
- drinking water
- metabolic syndrome
- advanced non small cell lung cancer
- young adults
- case report
- low grade
- chronic myeloid leukemia
- electronic health record
- acute care
- adverse drug